Divi's Laboratories Q3 FY26 results (Oct–Dec 2025) and concall

Divi's Laboratories reported a robust Q3 FY26, with consolidated total income growing to ₹2,692 crores and pre-exceptional profit before tax increasing to ₹854 crores, driven by improved operating performance and a favorable product mix. The company saw healthy volume traction in generics, active engagement in custom synthesis, and continued growth in nutraceuticals. Operational efficiencies and a successful FDA inspection underscored strong quality, though competitive pricing in generics and potential raw material cost pressures from China's policy changes remain areas of vigilance.